CA3220332A1 - Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines - Google Patents

Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines Download PDF

Info

Publication number
CA3220332A1
CA3220332A1 CA3220332A CA3220332A CA3220332A1 CA 3220332 A1 CA3220332 A1 CA 3220332A1 CA 3220332 A CA3220332 A CA 3220332A CA 3220332 A CA3220332 A CA 3220332A CA 3220332 A1 CA3220332 A1 CA 3220332A1
Authority
CA
Canada
Prior art keywords
composition
group
compound
tumor
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220332A
Other languages
English (en)
Inventor
Shaker Mousa
Mehdi Rajabi
Ozlem O. Karakus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoPharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/340,843 external-priority patent/US11351137B2/en
Application filed by Individual filed Critical Individual
Publication of CA3220332A1 publication Critical patent/CA3220332A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions chimiques et leurs procédés de synthèse. Les compositions de l'invention sont dirigées contre des antagonistes du récepteur de l'intégrine ???3 de l'hormone thyroïdienne conjugués à des cibles du transporteur de norépinéphrine (NET) ou du transporteur de catécholamine. Les compositions ont un effet de double ciblage et une efficacité de ciblage accrue dans le traitement et l'imagerie diagnostique de tumeurs neuroendocrines.
CA3220332A 2021-06-07 2022-06-02 Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines Pending CA3220332A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/340,843 2021-06-07
US17/340,843 US11351137B2 (en) 2018-04-11 2021-06-07 Composition and method for dual targeting in treatment of neuroendocrine tumors
PCT/US2022/031876 WO2022260918A1 (fr) 2021-06-07 2022-06-02 Composition et méthode de double ciblage dans le traitement de tumeurs neuroendocrines

Publications (1)

Publication Number Publication Date
CA3220332A1 true CA3220332A1 (fr) 2022-12-15

Family

ID=84425339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220332A Pending CA3220332A1 (fr) 2021-06-07 2022-06-02 Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines

Country Status (6)

Country Link
EP (1) EP4351650A4 (fr)
JP (1) JP2024520888A (fr)
CN (1) CN117412772A (fr)
AU (1) AU2022287943A1 (fr)
CA (1) CA3220332A1 (fr)
WO (1) WO2022260918A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
EP2275103B1 (fr) * 2005-11-21 2014-04-23 Novartis AG Inhibiteurs du mTOR pour le traitement des tumeurs endocriniennes
WO2009114776A2 (fr) * 2008-03-14 2009-09-17 Visen Medical, Inc. Agents de ciblage de l'intégrine, et procédés d’utilisation associés
WO2011123742A1 (fr) * 2010-04-01 2011-10-06 Baylor College Of Medicine Agents non radioactifs pour l'imagerie de neuroblastomes
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US10328043B1 (en) * 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) * 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors

Also Published As

Publication number Publication date
WO2022260918A1 (fr) 2022-12-15
EP4351650A4 (fr) 2025-06-04
AU2022287943A1 (en) 2023-12-07
CN117412772A (zh) 2024-01-16
JP2024520888A (ja) 2024-05-24
EP4351650A1 (fr) 2024-04-17

Similar Documents

Publication Publication Date Title
EP3773540B1 (fr) Composition et procédé de double ciblage dans le traitement de tumeurs neuroendocrines
CN111741751A (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
CN109153641B (zh) 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途
US11497819B2 (en) PSMA ligands for imaging and endoradiotherapy
KR20200011950A (ko) 방사성 의약품, 방사성 영상화제 및 이의 용도
US10709790B2 (en) Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
CA2405469A1 (fr) Composes a base de peptides
EP3209336A1 (fr) Inhibiteurs marqués 18f de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
JP6047581B2 (ja) 金属放射性医薬品のためのケージアミン配位子
CN111542518A (zh) 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途
JP2020097605A (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
AU2021264931A1 (en) Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention in brain tumors
US9364570B2 (en) Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
FR2967671A1 (fr) Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
US11351137B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2022260918A1 (fr) Composition et méthode de double ciblage dans le traitement de tumeurs neuroendocrines
JP7824281B2 (ja) ガストリン放出ペプチド受容体アンタゴニストを含むコンジュゲートまたはその塩およびそれらの使用
RU2789198C2 (ru) Композиция и способ двойного нацеливания при лечении нейроэндокринных опухолей
WO2010083154A2 (fr) Polymères de poly(éthylèneglycol) à segments hétérofonctionnels utilisés en tant que supports d'administration
HK40118167A (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
HK40029571B (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
CN119072485A (zh) 用于羟基磷灰石靶向显像和治疗的缀合物、组合物和方法
HK1259758A1 (en) Compounds for positron emission tomography

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523